Multivariate Analysis (MVA) of Progression-Free Survival (PFS) in Two Phase IIb, Multinational, Double-Blind, Randomized, Placebo (Pl)-Controlled Trials Evaluating Sorafenib (SOR) Plus Standard Chemotherapy in Patients (pts) with HER2-negative Locally Advanced or Metastatic Breast Cancer (BC).